Get started
Author

Lionel Martellet

Observed name: Martellet, Lionel
ORCID: 0000-0002-2454-4614
Observed ORCID: 0000-0002-2454-4614
OpenAlex ID: A5024301960
Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans
2011 · Samba O. Sow, Brown J. Okoko, et al. · New England Journal of Medicine · 178
PDF
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study
2018 · Wilbur H Chen, Kathleen M Neuzil, et al. · The Lancet Infectious Diseases · 86
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia
2023 · Fadima C. Haidara, Ama Umesi, et al. · New England Journal of Medicine · 44
PDF
Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers
2021 · Milagritos D. Tapia, Samba O. Sow, et al. · New England Journal of Medicine · 35
PDF
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2–10 years: A Phase II/III double-blind randomized controlled trial
2012 · Siddhivinayak Hirve, Ashish Bavdekar, et al. · Vaccine · 29
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
2015 · Aldiouma Diallo, Samba O. Sow, et al. · Clinical Infectious Diseases · 23
PDF
Conducting vaccine clinical trials in sub-Saharan Africa: Operational challenges and lessons learned from the Meningitis Vaccine Project
2012 · Elisa Marchetti, Véronique Mazarin-Diop, et al. · Vaccine · 22
Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
2015 · Milagritos D. Tapia, Helen Findlow, et al. · Clinical Infectious Diseases · 17
PDF
Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine
2015 · Lionel Martellet, Samba O. Sow, et al. · Clinical Infectious Diseases · 12
PDF
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial
2025 · Fatoumata Diallo, Fadima C Haidara, et al. · The Lancet · 11
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
2015 · Milagritos D. Tapia, Samba O. Sow, et al. · Clinical Infectious Diseases · 6
PDF
Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond
2025 · Mark R. Alderson, Katie Regan, et al. · Human Vaccines & Immunotherapeutics · 3
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons
2015 · Godwin C. Enwere, Gandhali Paranjape, et al. · Clinical Infectious Diseases · 3
PDF
Persistence of Serum Bactericidal Antibody in the First 2 Years After Immunization With Pentavalent Meningococcal ACWYX Vaccine in Malian Infants and Toddlers
2026 · Wilbur H Chen, Fadima C Haidara, et al. · Clinical Infectious Diseases
PDF
Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers
2025 · Abraham Hodgson, Fadima Cheick Haidara, et al. · Vaccine
Immunogenicity and Safety of Meningococcal ACWYX Conjugate Vaccine When Coadministered with Routine Childhood Vaccines at 9-Months and 15-Months of Age: A Randomised, Controlled, Phase 3, Non-Inferiority Trial
2024 · Fatoumata Diallo, Fadima Haidara, et al. · SSRN Electronic Journal
Works count: 17
Citation count: 469
H-index: 10
I10-index: 10
Year
Topic
Type